bit.bio

bit.bio is a Cambridge-based synthetic biology company providing human cells for research, drug discovery and cell therapy development. Spun out of the University of Cambridge in 2016, it uses opti-ox technology to reprogramme induced pluripotent stem cells into defined human cell types. Its portfolio spans more than 50 human cell types, including nerve, immune and muscle cells and disease models.

The company combines cell programming, stem cell science, manufacturing and clinical translation. Researchers and drug developers use its cells to investigate disease and test potential treatments. It also offers CRISPR screening services for functional genomics, helping customers study gene function in human cells and identify or validate drug targets.